ABCANN GLOBAL CORPORATION (CVE:ABCN) reported the launch of one of Canada’s highest legal Hemp:THC ratio items available on the market by its subsidiary, ABcann Medicinals Inc. The launch of Hemp-Med is part of the firm’s plan to offer a diverse range of offerings as it formally initiates the procedure to start selling oils. Hemp-Med showcases a ratio of 27.6:1, putting the product into an extremely select class as one of highest Hemp offerings under Health Canada regulations.
Besides formally offering this offerings to its patient base, ABcann is expecting being able to offer oils in October as it diversifies its product lines. Offerings that the company will have available for people are anticipated to include a 1-1 THC and Hemp drop, a high Hemp dropper and a high THC dropper. This new high Cannabinoid offering is in addition to company’s current high Cannabinoid products: NC:Med – 18.9:1 and DC:Med – 15.4:1.
ABcann will announce additional product details pertaining the formulations of soft gels and capsules shortly. Ken Clement, the Executive Chairman, reported that the advancement of these offerings is in line with its corporate plan as a top product provider of organic and pesticide free cannabis. As the firm continues to increase production capacity, the product line will expand as they strive to enhance shareholder value via capturing a larger chunk of the current international medical markets.
Aaron Keay, the CEO of ABcann, reported that the company will continue to advance its subsidiaries and core businesses as production capacity continues to surge through aggressive expansion and construction plans.
The construction timelines at company’s locations position it to become a strong peer in the current international medical market and to take benefit of the growing adult consumer market that is anticipated to emerge in 2018. ABcann continues to function under one of the top assurance programs in the world.